CMR Surgical: Galaxy Care Becomes First Hospital in the World to Acquire the Versius Surgical Robotic System
16.10.2019 07:00:00 EEST | Business Wire | Press release
CMR Surgical Ltd today announced that Galaxy Care Hospital in Pune, India, has become the first hospital in the world to procure Versius ® , a next-generation surgical robotic system. A range of surgical procedures have already been conducted using Versius® at the world-renowned centre for laparoscopy, including transthoracic, hysterectomies and myomectomies, under the leadership of Dr. Shailesh Puntambekar.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005940/en/
Galaxy Care is a well-established centre of excellence for laparoscopic surgery and the introduction of Versius ® will support the hospital to bring robotic-assisted laparoscopic surgery to more people. Dr Shailesh Puntambekar, Consultant Oncologist, Surgeon and Medical Director of Galaxy Care will lead the team using Versius ® . He is an international pioneer in surgery and renowned for his advanced laparoscopic skills. In addition to this, he is responsible for training laparoscopy to surgeons from all over the world, helping to bring the benefits of minimal access surgery to patients globally.
Dr Puntambekar has led the way in bringing surgical robotics to India, having performed robotic-assisted surgery in India for over a decade and will be responsible for the introduction of Versius ® to Galaxy Care. Versius ® as a next-generation surgical robotic system with its small form factor, versatility and portability has been designed to support surgeons to deliver the benefits of minimal access surgery to patients around the world.
“As an experienced surgeon in robotic assisted surgery I think that there is significant potential for Versius ® to further increase access to laparoscopic surgery for my patients, so it was a natural choice to acquire this system. Versius ® , as a small and cost-effective system is well suited for meeting the high surgical demand in India. We are excited to bring the next-generation surgical robot to India.” said Dr. Shailesh Puntambekar, Medical Director at Galaxy Care Hospital, Pune, India.
“Galaxy Care has become our first customer to acquire and use Versius ® and this is an important milestone in bringing the benefits of minimal access surgery to all. We are pleased to be working with a centre that has some of the best surgeons in the world, meeting a high surgical demand. It is important that we bring Versius ® to market responsibly and we are delighted to be working closely with Galaxy Care on the introduction of Versius ® in the hospital”, said Mark Slack, Chief Medical Officer, CMR Surgical.
The commercial introduction of Versius ® also marks the launch of the world’s first clinical registry for a surgical robotic system. The registry is part of CMR Surgical’s commitment to post-market surveillance as part of the IDEAL framework and a responsible introduction of a medical device. The clinical registry managed by CMR Surgical, working in partnership with customers is recording and monitoring the patient outcomes of all procedures conducted using the Versius ® Surgical Robotic System in order to ensure patient safety. Outcome measures being recorded include: operative time, length of stay, return to hospital within 30 days, and return to operating room within 24 hours.
In addition to the first global commercial deal taking place in India, the Versius® Surgical Robotic System is expected to be introduced in hospitals across Europe later in 2019.
---ENDS---
About the Galaxy Care Hospital, Pune, India
Galaxy Care Hospital located in Pune, India is a specialist centre in laparoscopic and Robotic cancer surgeries. It has the first and only robotic theatre in western and southern India. The hospital is led by Medical Director Dr. Shailesh Puntambekar who has performed a number of internationally acclaimed procedures including India’s first successful womb transplant as well as pioneering laparoscopic radical hysterectomy for early stage cervical cancer, known globally as the Pune technique. Galaxy Care is now associated with the Care Group of Hospitals, with a number of hospitals across India.
About the Clinical Registry
The clinical registry established by CMR Surgical, working in partnership with customers will support post-market surveillance for the Versius ® Surgical Robotic System. The clinical registry will be collecting the following clinical data on procedures conducted using Versius ® : patient demographics, surgical history, date of diagnosis, planned procedure, operative time, estimated blood loss, return to operating theatre within 24 hours, length of stay, return to hospital within 30 days, mortality at 90 days, any complications that may have occurred. All data is anonymised.
About the Versius® Surgical Robotic System
Versius® resets expectations of robotic surgery by providing a versatile system that is portable, transportable and affordable. This is made possible because of its elegant form factor, modular design and individually cart-mounted arms. Versius® can move between operating rooms and even hospitals/clinics and gives the surgical team excellent access to the patient at all times.
Biomimicking the human arm, Versius® allows surgeons the freedom of port placement, but with the benefits of small fully-wristed instruments. With 3D HD vision, easy-to adopt instrument control and a choice of ergonomic working positions, the new open surgeon console has the potential to reduce stress and fatigue and extend the careers of surgeons.
About CMR Surgical Limited
CMR Surgical is a British private limited company developing the next-generation universal robotic system, Versius®, for minimal access surgery. The company received the European CE Mark in March 2019 for the Versius® Surgical Robotic System.
The vision behind CMR Surgical is to make minimal access surgery universally accessible and affordable, transforming the existing market for surgical robotics while also addressing the six million people who still undergo open surgery each year.
Global annual revenues for robot-assisted minimal access surgery are presently approximately $4 billion and are anticipated to reach $20 billion by 2025.
CMR Surgical, formed in 2014, has its headquarters in Cambridge, United Kingdom and is backed by an international shareholder base of specialist and generalist investors.
The Company achieved the registration of its Quality Management System to ISO 13485:2016 by Underwriters Laboratories LLC® (UL), and the status as a UL Registered Firm, in September 2015.
For further information, please visit www.cmrsurgical.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005940/en/
Contact information
CMR Surgical
Patrick Pordage/ Sarah Ghabina
patrick.pordage@cmrsurgical.com/ sarah.ghabina@cmrsurgical.com
+44 (0)7864 922341 /+44 (0)7749 432373
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 02:01:00 EEST | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together, the companies will aim to develop a novel, tumour-selective therapeutic targeting a solid tumour antigen expressed across multiple difficult-to-treat cancer types. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615992992/en/ “Partnering with LG Chem represents a very important moment for LabGenius and provides further validation of our platform’s ability to design highly optimised multispecific antibodies,”said Dr. James Field, CEO of LabGenius. “We welcome this opp
Joe Vernachio Named President of SOREL18.6.2026 01:00:00 EEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 23:30:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 23:05:00 EEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
SES Announces Results of the Extraordinary General Meeting of Shareholders17.6.2026 20:23:00 EEST | Press release
SES (the “Company”) held an Extraordinary General Meeting (“EGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions. In particular, shareholders approved the cancellation of shares repurchased under the Company’s share buyback program of 2 November 2023, as amended on 2 May 2024, resulting in a corresponding reduction of the Company’s share capital. Shareholders also approved amendments to the Company’s articles of association, including indemnification for Board members and executives, as well as updates relating to the conduct of shareholder meetings. Detailed results on all matters voted on at the EGM will be available on the company’s webpage: https://www.ses.com/company/investors/shareholder-information/general-meeting-shareholders Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom